Immunovant Awarded U.S. Patent for IMVT-1402
March 12 2024 - 7:30AM
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage
immunology company dedicated to enabling normal lives for people
with autoimmune diseases, today announced that the United States
Patent and Trademark Office has issued U.S. Patent No. 11,926,669
(“the ‘669 patent”) for IMVT-1402, the Company’s second-generation
antibody targeting the neonatal fragment crystallizable receptor
(FcRn). The allowed claims cover composition of matter for the
binding sequence of IMVT-1402 to FcRn, method of use of the
antibody for treating autoimmune disease, as well as methods for
its manufacturing. Not including any potential patent term
extension, the ‘669 patent will expire on June 23, 2043. IMVT-1402
is being developed by Immunovant based on antibody discovery
efforts by HanAll Biopharma.
IMVT-1402 delivered subcutaneously has demonstrated potentially
best-in-class profile in a Phase 1 clinical trial in healthy
adults, with initial data demonstrating a deep immunoglobulin G
(IgG) reduction that is similar to batoclimab, but with no or
minimal changes in serum albumin and LDL cholesterol, consistent
with placebo. Immunovant believes that IMVT-1402 administered
weekly can achieve steady reductions in IgG and further believes
that steady reductions in IgG lowering are needed to avoid
fluctuations in efficacy.
About Immunovant, Inc.Immunovant, Inc. is a
clinical-stage immunology company dedicated to enabling normal
lives for people with autoimmune diseases. As a trailblazer in
anti-FcRn technology, the Company is developing innovative,
targeted therapies to meet the complex and variable needs of people
with autoimmune diseases. For additional information on the
Company, please visit www.immunovant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995 and other federal securities laws. The use of words
such as "can," “may,” “might,” “will,” “would,” “should,” “expect,”
“believe,” “estimate,” “design,” “plan,” "intend," and other
similar expressions are intended to identify forward-looking
statements. Such forward looking statements include statements
regarding Immunovant’s intellectual property portfolio;
Immunovant’s belief regarding the impact to IgG with IMVT-1402
administered on a weekly basis; and potential benefits of
IMVT-1402’s unique product attributes and potential best-in-class
profile. All forward-looking statements are based on estimates and
assumptions by Immunovant’s management that, although Immunovant
believes to be reasonable, are inherently uncertain. All
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those that
Immunovant expected. Such risks and uncertainties include, among
others: Immunovant may not be able to protect or enforce its
intellectual property rights; initial results or other preliminary
analyses or results of early clinical trials may not be predictive
final trial results or of the results of later clinical trials; the
timing and availability of data from clinical trials; the timing of
discussions with regulatory agencies, as well as regulatory
submissions and potential approvals; the continued development of
Immunovant’s product candidates, including the number and timing of
the commencement of additional clinical trials; Immunovant’s
scientific approach, clinical trial design, indication selection,
and general development progress; future clinical trials may not
confirm any safety, potency, or other product characteristics
described or assumed in this press release; any product candidate
that Immunovant develops may not progress through clinical
development or receive required regulatory approvals within
expected timelines or at all; Immunovant’s product candidates may
not be beneficial to patients, or even if approved by regulatory
authorities, successfully commercialized; the potential impact of
global factors, such as the post-COVID-19 environment, geopolitical
tensions, and adverse macroeconomic conditions on Immunovant’s
business operations and supply chain, including its clinical
development plans and timelines; Immunovant’s business is heavily
dependent on the successful development, regulatory approval and
commercialization of batoclimab and IMVT-1402; Immunovant is at an
early stage of development for IMVT-1402 and in various stages of
clinical development for batoclimab; and Immunovant will require
additional capital to fund its operations and advance batoclimab
and IMVT-1402 through clinical development. These and other risks
and uncertainties are more fully described in Immunovant’s periodic
and other reports filed with the Securities and Exchange Commission
(SEC), including in the section titled “Risk Factors” in
Immunovant’s Form 10-Q filed with the SEC on February 12, 2024, and
Immunovant’s subsequent filings with the SEC. Any forward-looking
statement speaks only as of the date on which it was made.
Immunovant undertakes no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
Contact:Chau Cheng, PhD, MBAVice President,
Investor RelationsImmunovant, Inc.info@immunovant.com
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From Apr 2024 to May 2024
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From May 2023 to May 2024